Haemonetics Co. (NYSE:HAE) Forecasted to Earn FY2026 Earnings of $4.80 Per Share

Haemonetics Co. (NYSE:HAE - Free Report) - Barrington Research reduced their FY2026 EPS estimates for shares of Haemonetics in a research report issued to clients and investors on Friday, April 12th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $4.80 for the year, down from their previous estimate of $4.85. Barrington Research currently has a "Outperform" rating and a $105.00 target price on the stock. The consensus estimate for Haemonetics' current full-year earnings is $3.95 per share. Barrington Research also issued estimates for Haemonetics' FY2027 earnings at $5.52 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.10. The firm had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company's revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.85 earnings per share.

HAE has been the subject of a number of other reports. TheStreet lowered shares of Haemonetics from a "b-" rating to a "c+" rating in a report on Thursday, February 29th. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a report on Friday, March 22nd.

Haemonetics Price Performance

HAE traded down $0.31 during midday trading on Monday, hitting $84.91. The stock had a trading volume of 318,187 shares, compared to its average volume of 446,562. Haemonetics has a 1 year low of $70.74 and a 1 year high of $95.26. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The business has a fifty day moving average of $78.42 and a 200 day moving average of $82.80. The company has a market cap of $4.31 billion, a P/E ratio of 34.52, a price-to-earnings-growth ratio of 2.01 and a beta of 0.36.

Institutional Investors Weigh In On Haemonetics

Large investors have recently modified their holdings of the stock. American Century Companies Inc. lifted its holdings in Haemonetics by 163.5% in the first quarter. American Century Companies Inc. now owns 17,407 shares of the medical instruments supplier's stock worth $1,100,000 after buying an additional 10,802 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Haemonetics by 3.1% during the first quarter. PNC Financial Services Group Inc. now owns 12,802 shares of the medical instruments supplier's stock valued at $809,000 after purchasing an additional 387 shares in the last quarter. Bank of Montreal Can grew its stake in Haemonetics by 300.3% in the first quarter. Bank of Montreal Can now owns 33,039 shares of the medical instruments supplier's stock worth $2,033,000 after purchasing an additional 24,785 shares during the period. Rhumbline Advisers raised its holdings in Haemonetics by 1.9% in the first quarter. Rhumbline Advisers now owns 148,770 shares of the medical instruments supplier's stock worth $9,405,000 after purchasing an additional 2,817 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Haemonetics by 10.6% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,732 shares of the medical instruments supplier's stock valued at $1,184,000 after buying an additional 1,788 shares during the period. Institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.